Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage oncology company with Nasdaq-traded American depositary shares. Form 6-K reports furnish investor presentations, fact sheets, clinical updates for paxalisib, material-event disclosures, operating and financial results, and updates related to the company's oncology pipeline.
The filing record also covers capital structure and financing activity, including ADS sales agreements, registration-statement references, private placements, ordinary shares, pre-funded warrants, and placement-agent warrants. Governance disclosures include annual general meeting results, director and committee changes, and shareholder voting matters. Material-agreement filings describe licensing arrangements such as the SETDB1-targeted epigenetic platform, while risk and forward-looking disclosures address development-stage biotechnology, regulatory plans, clinical programs, and capital-market compliance.
Kazia Therapeutics director Ebru Davidson has filed an initial ownership report outlining existing option-based exposure to the company’s American Depositary Shares (ADSs). The filing shows two ADS option positions, each giving the right to buy ADSs at fixed exercise prices before their respective expiration dates.
One ADS option covers 75,000 underlying ADSs at an exercise price of $8.0000 per ADS, expiring on July 3, 2027. Another ADS option covers 2,000 underlying ADSs at an exercise price of $0.3348 per ADS, expiring on April 30, 2027. Footnotes explain that one grant vests in equal quarterly installments over three years beginning April 30, 2024, while another vested 100% on July 3, 2025, in each case conditioned on continued service.
Kazia Therapeutics files a prospectus supplement registering 10,700,211 American Depositary Shares, representing 5,350,105,500 ordinary shares. The supplement incorporates a Form 6-K furnished June 2, 2026, which discloses the appointment of James Levine as Chief Financial Officer, effective June 1, 2026.
Mr. Levine’s employment terms include an annual base salary of $475,000, an annual target bonus equal to 40% of base salary (prorated for 2026), and a proposed grant, subject to Board approval, of options over 200,000 ADSs with one-third vesting on commencement and the balance vesting in equal yearly installments. Severance and post-termination benefits are described in the Employment Agreement filed as Exhibit 10.1.
Kazia Therapeutics Limited files a prospectus supplement registering 232,956 American Depositary Shares. The supplement, dated June 2, 2026, incorporates a Form 6-K that announces the appointment of James Levine as Chief Financial Officer effective June 1, 2026, and summarizes his employment terms.
The prospectus supplement states the ADSs trade on Nasdaq under the symbol KZIA and notes a reported last sale price of $12.56 per ADS as of June 1, 2026. The Form 6-K discloses Mr. Levine’s US$475,000 base salary, a 40% target bonus (prorated for 2026), and a 200,000 ADS option grant subject to Board approval and vesting terms. Employment and severance provisions are summarized in the furnished Employment Agreement (Exhibit 10.1).
Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares (ADSs) as set forth on the prospectus supplement dated June 2, 2026. The supplement incorporates a Form 6-K reporting the appointment of James Levine as Chief Financial Officer, effective June 1, 2026, and summarizes his employment terms.
The prospectus supplement discloses that the ADSs trade on Nasdaq under the symbol KZIA and notes a last reported sale price of $12.56 per ADS on June 1, 2026. The Form 6-K describes Mr. Levine’s compensation package, including a $475,000 base salary, a 40% target bonus (prorated for 2026), and a proposed grant of 200,000 ADS options subject to Board approval and vesting conditions.
Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares (ADSs) representing 47,555,000 Ordinary Shares as described on the supplement cover. The supplement incorporates a Form 6-K dated June 2, 2026 and updates the Prospectus dated December 22, 2025.
The Form 6-K included in the supplement furnishes a press release announcing the appointment of James Levine as Chief Financial Officer effective June 1, 2026, and summarizes his employment terms: a $475,000 base salary, a 40% target bonus (prorated for 2026), and a proposed grant of 200,000 ADS options subject to Board approval and vesting terms. The ADSs trade on Nasdaq under the symbol KZIA.
Kazia Therapeutics Limited has appointed James Levine as Chief Financial Officer, effective June 1, 2026. Under his employment agreement, he will receive an annual base salary of US$475,000, an annual target bonus equal to 40% of base salary (prorated for 2026), and options over 200,000 American Depositary Shares.
One-third of the options vest at the start of employment, with the rest vesting in equal yearly installments, and all options are forfeited if he leaves voluntarily within the first year. If his role ends without cause or he resigns for good reason, he may receive up to 12 months’ salary and health coverage in certain change-in-control situations, or up to 6 months’ salary and health coverage otherwise, subject to conditions including a release of claims.
Kazia Therapeutics Ltd reports beneficial ownership of 2,114,649 American Depositary Shares, representing 18.5% of the class as of May 26, 2026. The filing calculates the class base on 11,426,899 ADS outstanding as of March 12, 2026, per the issuer's Form F-3. The schedule lists the reporting person as Jorey Chernett with sole voting and dispositive power over the disclosed ADS.
Kazia Therapeutics is supplementing its registration materials to cover 232,956 American Depositary Shares, representing 116,478,000 Ordinary Shares. The supplement incorporates a May 26, 2026 Form 6-K announcing expansion of a Phase 1b paxalisib trial in advanced triple negative breast cancer: planned enrollment will increase from 12 to 36 patients to further assess safety, dose optimization and preliminary efficacy. The press release notes continued encouraging safety and tolerability and anticipates additional updates through 2026 into 2027.
Kazia Therapeutics Limited filed a prospectus supplement registering 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares and furnished a Form 6-K attaching a May 26, 2026 press release. The release announces an expansion of its Phase 1b paxalisib trial in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients based on continued encouraging safety and tolerability data. The supplement updates the Prospectus dated December 22, 2025 and attaches the press release; the ADSs trade on Nasdaq under the symbol KZIA.
Kazia Therapeutics filed a prospectus supplement dated May 26, 2026 registering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares as part of its Form F-1 registration. The supplement incorporates a Form 6-K announcing an expansion of its ongoing Phase 1b trial of paxalisib in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients to further evaluate safety, dose optimization and preliminary efficacy. The ADSs trade on Nasdaq under the symbol KZIA, with a reported last sale price of $13.66 per ADS on May 22, 2026. Additional clinical updates are expected through 2026 and into 2027.